ויקטוזה - Victoza

× ×ª×× × ×ª×¨××¤×

××¦××ª

××××¨××

××××¢ × ××¡×£

×¡×¨××× ××

××¨×¦×××ª

×©××× ××Â !
××ª××¨××: 10/12/2024 ××ª×§××× ××××¢× ×× ×©××××§ ××ª×¨××¤× ×××¤×¡×§ ××¦×××ª××ª.

× ×ª×× × ×ª×¨××¤×

××¡× ×××¨××××ª

×××¨×©×

×§×××¦× ×¤×¨××§××××××ª (ATC4)

A10BJ
Glucagon-like peptide-1 (GLP-1) analogues

××¨××× ×¤×¢×× (ATC5)

Liraglutide 6.0MG/ML âA10BJ02

×¦××¨×ª ××ª×

×ª×ª-×¢××¨× - S.C

×¦××¨×ª ××× ××

×ª×××¡× ××××¨×§×, SOLUTION FOR INJECTION
××× ××¢×ª ××× ×× ××ª×¨ ×× ××¨×¢×× ××© ××××× ××ª ××ª×¨××¤× ×××ª×× ×××× ×× ××××××¥ ××¤× ×©×××¤××¢ ××¢××× ××¦×¨××

××ª××××

Victoza is indicated for:â¢ Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

As monotherapy when metformin is considered inappropriate due to intolerance or contraindications 2. In addition to other medicinal products for the treatment of diabetes. â¢ To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.

× ×ª×× × ××¡×

×ª××¨×× ××××× ××¡×

03/01/2010

××××××ª ××¡×

×ª×¨××¤× ××××××ª ××¨××©×× ×¢'× ×¨××¤× ××××× ×× ××××× ×××¨×ª

××ª×××× ××¡×

××ª××××	×ª××¨×× ×××××	×ª××× ×§××× ×	Class Effect	××¦× ××××
×. ××ª×¨××¤× ×ª×× ×ª× ××××¤×× ××××× ×¡×××¨×ª ×¡×× 2 ××¢×× ×× ×¢× ×× ×××: 1. BMI ××¢× 30; 2. HbA1c ××¢× 8; 3. ×× ×¡××× ××¢××¨ ××¤× ×§×¨××××××¡ ×× ××× × ××¨×; 4. ××× × ×¡××××× ××× ×¡×¤××§× ×××××ª××ª (×§×¨×××× ×× ××¢× 1.5); 5. ××××¨ ×××¦×× ××××¤×× ××ª×¨××¤×ª× ××©×ª× ×ª×¨××¤××ª ×¤×××××ª, ××× ××¤×××ª. ×. ××××¤×× ×× ××× ×ª× ××©×××× ×¢× ××× ×¡××××.	03/01/2010	×× ×××§×¨×× ××××××	LIRAGLUTIDE, EXENATIDE	×¡×××¨×ª ×¡×× 2, Diabetes
1. ××××¤×× ××××× ×¡×××¨×ª ×¡×× 2 ××¢×× ×× ×¢× ×× ×××: ×. BMI ××¢× 30; ×. HbA1c ××¢× 7.5; ×. ×× ×¡××× ××¢××¨ ××¤× ×§×¨××××××¡ ×× ××× × ××¨×; ×. ××× × ×¡××××× ××× ×¡×¤××§× ×××××ª××ª (×§×¨×××× ×× ××¢× 1.5); ×. ××××¨ ×××¦×× ××××¤×× ××ª×¨××¤×ª× ××©×ª× ×ª×¨××¤××ª ×¤×××××ª, ××× ××¤×××ª; 2. ××××¤×× ×× ××× ×ª× ××©×××× ×¢× ××× ×¡××××.	10/01/2012	×× ×××§×¨×× ××××××	LIRAGLUTIDE, EXENATIDE	×¡×××¨×ª ×¡×× 2, Diabetes
×××¤×× ××××× ×¡×××¨×ª ×¡×× 2 ××¢×× ×× ×¢× ×× ×××: 1. BMI ××¢× 30; 2. HbA1c ××¢× 7.5; 3. ×× ×¡××× ××¢××¨ ××¤× ×§×¨××××××¡; (××¨×××ª ××¡××¨×ª ×××××× ××¡×) 4. ××× × ×¡××××× ××× ×¡×¤××§× ×××××ª××ª (×§×¨×××× ×× ××¢× 1.5); 5. ××××¨ ×××¦×× ××××¤×× ××ª×¨××¤×ª× ××©×ª× ×ª×¨××¤××ª ×¤×××××ª, ××× ××¤×××ª.	09/01/2013	×× ×××§×¨×× ××××××	LIRAGLUTIDE, EXENATIDE	×¡×××¨×ª ×¡×× 2, Diabetes
×××¤×× ××××× ×¡×××¨×ª ×¡×× 2 ××¢×× ×× ×¢× ×× ×××: 1. ××¢×× ×× ×¢× ××× ××××: ×. BMI ××¢× 30 ×-HbA1c ××¢× 7.5; ×. BMI ××× 28-30 ×-HbA1c ××¢× 9.0; 2. ×× ×¡××× ××¢××¨ ××¤× ×§×¨××××××¡; 3. ××× × ×¡××××× ××× ×¡×¤××§× ×××××ª××ª (×§×¨×××× ×× ××¢× 1.5); 4. ××××¨ ×××¦×× ××××¤×× ××ª×¨××¤×ª× ××©×ª× ×ª×¨××¤××ª ×¤×××××ª, ××× ××¤×××ª.	15/01/2015	×× ×××§×¨×× ××××××	LIRAGLUTIDE, LIXISENATIDE, EXENATIDE	×¡×××¨×ª ×¡×× 2, Diabetes
×××¤×× ××××× ×¡×××¨×ª ×¡×× 2 ××¢×× ×× ×¢× ×× ×××: 1. ××¢×× ×× ×¢× ××× ××××: ×. BMI ××¢× 30 ×-HbA1c ××¢× 7.5%; ×. BMI ××× 28-30 ×-HbA1c ××¢× 9.0%; ×. BMI ××× 28-30 ×-HbA1c ××× 7.5 ×-9.0% ×××××× ×××× ×××××× â ××××ª ×× ××××××ª, ×××× ×¡×¨××¨×××¡×§×××¨××ª, ××××ª ×××× ××¨×× ××ª. 2. ×× ×¡××× ××¢××¨ ××¤× ×§×¨××××××¡; 3. ××× × ×¡××××× ××× ×¡×¤××§× ×××××ª××ª (×§×¨×××× ×× ××¢× 1.5); 4. ××××¨ ×××¦×× ××××¤×× ××ª×¨××¤×ª× ××©×ª× ×ª×¨××¤××ª ×¤×××××ª, ××× ××¤×××ª.	11/01/2018	×× ×××§×¨×× ××××××	LIRAGLUTIDE, LIXISENATIDE, DULAGLUTIDE, EXENATIDE	×¡×××¨×ª ×¡×× 2, Diabetes
×××¤×× ××××× ×¡×××¨×ª ×¡×× 2 ××¢×× ×× ×¢× ×× ×××: ×. ×¢×¨× HbA1c 7.5% ×××¢×× ××¢×× ×× ×¢× ××× ××××: 1. ×¢× BMI ××¢×¨× 28 ×××¢××; 2. ×¢× BMI ××¢×¨× 25 ×××¢××, ×××××× ×××× ×××××× â ××××ª ×× ××××××ª, ×××× ×¡×¨××¨×××¡×§×××¨××ª, ××××ª ×××× ××¨×× ××ª, ××××ª ××× ×× ×¤×¨××¤×¨××ª - (PVD - Peripheral vascular disease). ×. ×× ×¡××× ××¢××¨ ××¤× ×§×¨××××××¡; ×. ××× × ×¡××××× ××× ×¡×¤××§× ×××××ª××ª (×§×¨×××× ×× ××¢× 1.5); ×. ××××¨ ×××¦×× ××××¤×× ××ª×¨××¤×ª× ××©×ª× ×ª×¨××¤××ª ×¤×××××ª, ××× ××¤×××ª.	03/01/2021	×× ×××§×¨×× ××××××	LIRAGLUTIDE, LIXISENATIDE, DULAGLUTIDE, EXENATIDE	×¡×××¨×ª ×¡×× 2, Diabetes
××××× ×××ª×××¨×× ×××× ×¡×××¨×ª ×¡×× 2 ×¢× HbA1c ××¢×¨× ×©× 7% ×××¢××, ××××¨ ×××¦×× ××××¤×× ××××¤××¨××× ×× ×× ×¡×××××ª ××××¤××¨×××	03/02/2022	×× ×××§×¨×× ××××××		×¡×××¨×ª ×¡×× 2, Diabetes
×. ×¢×¨× HbA1c 7.5% ×××¢××, ×¢× BMI ××¢×¨× 28 ×××¢××, ××××¨ ×××¦×× ××××¤×× ××ª×¨××¤×ª× ××©×ª× ×ª×¨××¤××ª ×¤×××××ª, ××× ××¤×××ª, ×××©×¨ ×× ×¡××× ××¢××¨ ××¤× ×§×¨××××××¡. ×. ×¢×¨× HbA1c 7.5% ×××¢××, ×¢× BMI ××¢×¨× 25 ×××¢××, ×××××× ×××× ×××××× â ××××ª ×× ××××××ª, ×××× ×¡×¨××¨×××¡×§×××¨××ª, ××××ª ×××× ××¨×× ××ª, ××××ª ××× ×× ×¤×¨××¤×¨××ª - (PVD - Peripheral vascular disease), ××××¨ ×××¦×× ××××¤×× ××ª×¨××¤×ª× ××ª×¨××¤× ×¤××××ª ×××ª ××× ××¤×××ª, ×××©×¨ ×× ×¡××× ××¢××¨ ××¤× ×§×¨××××××¡. ×. ×¢×¨× HbA1c ××× 7.0-7.5%, ×¢× BMI ××¢×¨× 25 ×××¢××, ×××××× ×××× ×××××× - ××××ª ×× ××××××ª, ×××× ×¡×¨××¨×××¡×§×××¨××ª, ××××ª ×××× ××¨×× ××ª, ××××ª ××× ×× ×¤×¨××¤×¨××ª - (PVD - Peripheral vascular disease), ××××¨ ×××¦×× ××××¤×× ××ª×¨××¤×ª× ××©×ª× ×ª×¨××¤××ª ×¤×××××ª ××× ××¤×××ª, ×××©×¨ ×× ×¡××× ××¢××¨ ××¤× ×§×¨××××××¡.	19/02/2025	×× ×××§×¨×× ××××××	LIRAGLUTIDE, LIXISENATIDE, DULAGLUTIDE, SEMAGLUTIDE, EXENATIDE	×¡×××¨×ª ×¡×× 2, Diabetes

××¡××¨×ª ××××× ××¡×

××ª×¨××¤× ×ª×× ×ª× ××××¤×× ××××× ×¡×××¨×ª ×¡×× 2 ××¢×× ×× ×¢× ××× ××××:

×¢×¨× 7.5 ×××××× HbA1c ×××¢×× ×¢× BMI ××¢×¨× 28 ×××¢××, ××××¨ ×××¦×× ××××¤×× ××ª×¨××¤×ª× ××©×ª× ×ª×¨××¤××ª ×¤×××××ª, ××× ××¤×××ª, ×××©×¨ ×× ×¡××× ××¢××¨ ××¤× ×§×¨××××××¡
×¢×¨× 7.5 ×××××× HbA1c ×××¢×× ×¢× BMI ××¢×¨× 25 ×××¢××, ×××××× ×××× ×××××× - ××××ª ×× ××××××ª, ×××× ×¡×¨××¨×××¡×§×××¨××ª, ××××ª ×××× ××¨×× ××ª, ××××ª ××× ×× ×¤×¨××¤×¨××ª - Peripheral vascular disease â(PVD), ××××¨ ×××¦×× ××××¤×× ××ª×¨××¤×ª× ××ª×¨××¤× ×¤××××ª ×××ª, ××× ××¤×××ª, ×××©×¨ ×× ×¡××× ××¢××¨ ××¤× ×§×¨××××××¡
×¢×¨× HbA1c ××× 7.0-7.5 ××××××, ×¢× BMI ××¢×¨× 25 ×××¢××, ×××××× ×××× ×××××× - ××××ª ×× ××××××ª, ×××× ×¡×¨××¨×××¡×§×××¨××ª, ××××ª ×××× ××¨×× ××ª, ××××ª ××× ×× ×¤×¨××¤×¨××ª - Peripheral vascular disease â(PVD), ××××¨ ×××¦×× ××××¤×× ××ª×¨××¤×ª× ××©×ª× ×ª×¨××¤××ª ×¤×××××ª ××× ××¤×××ª, ×××©×¨ ×× ×¡××× ××¢××¨ ××¤× ×§×¨××××××¡

×¢××× ××¨××¤× ×××××¨××ª ××¢×××

×¢××× ××¨××¤× 23.02.2021

×¢××× ××¦×¨××	Â ×¢××× ××¦×¨×× ×¢××¨××ª (×¢××××) 23.03.2021 ×¢××× ××¦×¨×× ×¢××¨××ª 23.02.2021 ×¢××× ××¦×¨×× ×¢×¨×××ª - ÙØ´Ø±Ø© ÙÙÙØ³ØªÙÙÙ Ø¨Ø§ÙÙØºØ© Ø§ÙØ¹Ø±Ø¨ÙØ© - ÙØ´Ø±Ø© ÙÙÙØ³ØªÙÙÙ Ø¨Ø§ÙÙØºØ© Ø§ÙØ¹Ø±Ø¨ÙØ© 15.10.2020 ×¢××× ××¦×¨×× ×× ××××ª - Patient information leafletâ 15.10.2020

×¢××× ××¦×¨××

×¢×¨××× ×××××§××¨×¤×××	×¢×¨××× ×§×©××¨×× ×××××§××¨×¤×××
×××§×××× ×××××¨ ××©×¨× ×××¨××××ª

×××¤××© ××××¨××	××××¨×× ×-PubMed
××××¢ ××¨×©×ª	RxList WebMD Drugs.com
×©× ××¦×¨×	NOVO NORDISK A/S, DENMARK
×©× ××¢× ××¨××©××	NOVO NORDISK LTD, ISRAEL
×¨××©×××	×ª××¨×× ×××©×: 08/2009. ×¨××©××× ××ª××¨××: 02/2015
×ª××¨×× ×¢×××× ×××¨××	10/12/2024

×ª××× ×ª ××¨×××

×ª××× ×ª ××¨×××

××××¨××

××¦×¤××× ×××××¢ ×××¨×× ××¨××¤××× ××© ××××× ×¡ ×××©××× ×. ×× ××× × ×¨×©×× ××× ×¡ ×××¨×©×× ××¨××¤××× ××× ×©× ××§×¦××¢××ª ×¨×¤×××××.

השינוי האחרון נעשה בֹ־8 בפברואר 2025 ב־19:54

ויקטוזה - Victoza

ויקיתרופות